Basic Information | Post buying leads | Suppliers | Cas Database |
IARC Cancer Review: Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 26 (1981),p. 97.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.
1. Introduction of Bleomycin sulfate
Bleomycin sulfate is one kind of white powder. It is soluble in water, methanol, slightly soluble in ethanol, practically insoluble in acetone, ethyl acetate, butyl acetate, ethyl ether. The Product Categories of this chemical is Active Pharmaceutical Ingredients; UVCBs-biological; Intermediates & Fine Chemicals; Pharmaceuticals. The Classification Code of Bleomycin sulfate is Antineoplastic; Drug / Therapeutic Agent; Human Data; Mutation data; Reproductive Effect; Tumor data.
2. Properties of Bleomycin sulfate
Physical properties about Bleomycin sulfate are:
(1)Storage Temp. 2-8 °C; (2)Water Solubility: 20 mg/mL; (3)H-Bond Donor: 21; (4)H-Bond Acceptor: 33; (5)Rotatable Bond Count: 36; (6)Tautomer Count: 1000; (7)Exact Mass: 1511.478534; (8)MonoIsotopic Mass: 1511.478534; (9)Topological Polar Surface Area: 705; (10)Heavy Atom Count: 101.
3. Structure Descriptors of Bleomycin sulfate
(1)Canonical SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-]
(2)InChIKey: WUIABRMSWOKTOF-OCBSMOPSSA-N
(3)Smiles: S([O-])(=O)(=O)O.O1[C@H](O[C@@H]2[C@@H](O[C@H]([C@H]([C@@H]2O)O)CO)O[C@@H]([C@@H](C(N[C@@H]([C@@H]([C@@H](C(N[C@@H](C(=O)NCCc2nc(c3nc(C(=O)NCCC[S+](C)C)cs3)cs2)[C@@H](O)C)=O)C)O)C)=O)NC(c2nc([C@@H](CC(=O)N)NC[C@@H](C(=O)N)N)nc(c2C)N)=O)c2nc[nH]c2)[C@H]([C@H]([C@@H](O)[C@H]1CO)OC(N)=O)O
(4)InChI: InChI=1S/C55H83N17O21S3.H2O4S/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6;1-5(2,3)4/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88);(H2,1,2,3,4)/t21?,22?,23?,24?,25?,29-,30+,34?,35?,36?,37+,38+,39-,40-,41?,42-,43-,53+,54-;/m0./s1
4. Toxicity of Bleomycin sulfate
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | LDLo | unreported | .286units/kg (.286units/kg) | LUNGS, THORAX, OR RESPIRATION: FIBROSIS (INTERSTITIAL) LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA | Southern Medical Journal. Vol. 80, Pg. 646, 1987. |
mouse | LD50 | intraperitoneal | 210mg/kg (210mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 17, Pg. 455, 1975. | |
mouse | LD50 | subcutaneous | 103mg/kg (103mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
mouse | LDLo | intramuscular | 74mg/kg (74mg/kg) | BEHAVIORAL: ATAXIA | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
rat | LD50 | intraperitoneal | 240mg/kg (240mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. | |
rat | LD50 | subcutaneous | 86mg/kg (86mg/kg) | SKIN AND APPENDAGES (SKIN): HAIR: OTHER GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
rat | LDLo | intramuscular | 59mg/kg (59mg/kg) | BEHAVIORAL: ATAXIA | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
women | TDLo | parenteral | 20ug/kg (.02mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" LUNGS, THORAX, OR RESPIRATION: CYANOSIS | Arthritis and Rheumatism. Vol. 28, Pg. 459, 1985. |
1. | dnr-esc 20 µmol/L | MUREAV Mutation Research. 164 (1986),19. | ||
2. | hma-mus/esc 10 mg/kg | MUREAV Mutation Research. 164 (1986),19. | ||
3. | par-wmn TDLo:20 µg/kg:PUL,SKN | ARHEAW Arthritis and Rheumatism. 28 (1985),459. | ||
4. | ipr-rat LD50:240 mg/kg | IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. 7 (1976),108. | ||
5. | scu-rat LD50:86 mg/kg | JJANAX Japanese Journal of Antibiotics. 29 (1976),894. | ||
6. | ipr-mus LD50:210 mg/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 17 (1975),455. | ||
7. | scu-mus LD50:103 mg/kg | JJANAX Japanese Journal of Antibiotics. 29 (1976),894. |